Meta Biomed Co. Ltd (059210) — Cash Flow-to-Debt Ratio
Meta Biomed Co. Ltd (059210) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of ₩1.05 Billion could theoretically repay 0% of its total liabilities (₩58.87 Billion) in one year. See Meta Biomed Co. Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Meta Biomed Co. Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Meta Biomed Co. Ltd across 14 annual periods. Also explore Meta Biomed Co. Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Meta Biomed Co. Ltd (2011–2024)
Year-by-year debt coverage analysis for Meta Biomed Co. Ltd. For market capitalisation and broader financial context, see 059210 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | ₩22.63 Billion | ₩83.96 Billion | ▲ +51.6% |
| 2023 | 0.18x | ₩10.22 Billion | ₩57.46 Billion | ▲ +17.4% |
| 2022 | 0.15x | ₩9.16 Billion | ₩60.48 Billion | ▼ -39.1% |
| 2021 | 0.25x | ₩11.14 Billion | ₩44.80 Billion | ▲ +206.1% |
| 2020 | 0.08x | ₩4.86 Billion | ₩59.88 Billion | ▲ +41.8% |
| 2019 | 0.06x | ₩2.86 Billion | ₩50.02 Billion | ▲ +151.7% |
| 2018 | -0.11x | ₩-5.28 Billion | ₩47.72 Billion | ▼ -3180.8% |
| 2017 | 0.00x | ₩-248.51 Million | ₩73.65 Billion | ▼ -104.6% |
| 2016 | 0.07x | ₩5.03 Billion | ₩68.49 Billion | ▼ -6.3% |
| 2015 | 0.08x | ₩4.93 Billion | ₩62.91 Billion | ▲ +1975.5% |
| 2014 | 0.00x | ₩-296.24 Million | ₩70.85 Billion | ▼ -108.1% |
| 2013 | 0.05x | ₩3.71 Billion | ₩72.25 Billion | ▼ -16.1% |
| 2012 | 0.06x | ₩3.83 Billion | ₩62.54 Billion | ▼ -77.8% |
| 2011 | 0.28x | ₩4.10 Billion | ₩14.84 Billion | — |